#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: https://bit.ly/mm1oa-ea02-study
#ClinicalTrial EAF223/GABLE, led by Dr. Daniel Barboriak of @DukeRadiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: https://bit.ly/gable-trial
#FindingsFriday: New in @JCOOP_ASCO - The EROS trial shows a multilevel #ReproductiveHealth intervention significantly improved care aligned with patients’ goals after a cancer diagnosis (65.7% vs 47.3%). Learn more: #PatientCenteredCare #Oncofertility
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11 | JCO...
PURPOSEFor the 10% of women diagnosed with cancer within reproductive age, reproductive health is a critical component...
bit.ly
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites

Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
